ライフサイエンスコーパス: Cmax

1 Cmax, volume of distribution/bioavailability (Vd/F), and

2 ithin equivalence limits (AUC 90% CI 98-103, Cmax 90% CI 99-105), showing that lamotrigine exposures

3 r the concentration-time curve (AUC) by 35%, Cmax by 28%, and Cmin by 46%, consistent with induction

4 or log-transformed variables: AUC0-96, 2.58; Cmax, 0.64; and AUC0-infinity, 4.05; P >/= .13) and that

5 the predicted oral dose of CsA-ME produced a Cmax > 700 ng/ml in 90% of patients from days 2 to 4, an

6 the predicted oral dose of CsA-GC produced a Cmax > 700 ng/ml in only 64 and 82% of patients during t

7 met for all product comparisons for AUC and Cmax in both individuals with a kidney transplant and th

8 linearly related to the chylomicron AUC and Cmax values for alpha-carotene, lycopene, phylloquinone,

9 a linear increase in the chylomicron AUC and Cmax values for beta-carotene.

10 4.65%-118.13% and 80.00%-125.00% for AUC and Cmax, respectively.

11 under the concentration-time curve (AUC) and Cmax were seen with linear increases in administered dos

12 s, resulting in relative bioavailability and Cmax values 10- and 8.4-fold higher, respectively, confi

13 ent with a CrCl of 23.8 ml/min, the Cmin and Cmax were 0.32 and 0.7 microg/ml, respectively, with an

14 /ml; with CrCl of 25-50 ml/min, the Cmin and Cmax were 0.41+/-0.27 and 1.17+/-0.32 microg/ml, respect

15 With CrCl of <10 ml/min, the mean Cmin and Cmax were 0.75+/-0.42 and 1.59+/-0.55 microg/ml, respect

16 /ml; with CrCl of 50-69 ml/min, the Cmin and Cmax were 1.93+/-0.48 and 2.57+/-0.39 microg/ml, respect

17 Significantly higher AUC, SUV, and Cmax were observed in tumors in phase I studies.

18 tration to in vitro response ratio approach (Cmax/AC50), analogous to decision-making methods for cli

19 The 90% CIs of the ratios of both Cmax and AUC were within equivalence limits (AUC 90% CI

20 The maximum concentration Cmax and area under the concentration-time curve (AUC) f

21 The mean maximum concentration (Cmax) at a reasonably well-tolerated dose (50 mg orally

22 than 0.05 mumol/L and maximum concentration (Cmax) of paclitaxel.

23 range) plasma arsenic maximum concentration (Cmax) was 0.28 microM (0.11-0.37 microM) and at 0.2 mg/k

24 centration (Cmin) and maximum concentration (Cmax) were 0.78+/-0.46 microg/ml and 1.42+/-0.37 microg/

25 ours (AUC(0-24h)) and maximum concentration (Cmax) were calculated.

26 icant accumulation in maximum concentration (Cmax), and the intersubject variabilities (coefficient o

27 the curve (AUC0-24), maximum concentration (Cmax), AUC0-24/MIC, Cmax/MIC, and percentage of time tha

28 exposure (AUC(0-t) ) and peak concentration (Cmax) ratios of generic and reference formulations durin

29 Temsirolimus peak concentration (Cmax), and sirolimus Cmax and area under the concentrati

30 d concentration (C[av]), peak concentration (Cmax), and time to Cmax (tmax) values were calculated fr

31 rates IC(50), slope, and peak concentration (Cmax), correlated with improved complete cytogenetic res

32 bolites with a maximum plasma concentration (Cmax) 1 hour after ingestion.

33 Maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC)

34 comparison of maximum plasma concentration (Cmax) and area under the concentration-time curve (AUC)

35 increased the maximal plasma concentration (Cmax) and area under the time-concentration curve in rat

36 se with a mean maximum plasma concentration (Cmax) of 5.97 +/- 2.25 microg/mL and an area under the c

37 The mean DSM265 peak plasma concentration (Cmax) ranged between 1310 ng/mL and 34 800 ng/mL and was

38 AUC), maximum observed plasma concentration (Cmax), and time above a threshold concentration.

39 n steady-state maximum plasma concentration (Cmax,ss) and area under the steady-state plasma concentr

40 eight-adjusted maximum plasma concentration (Cmax/dose/kg) were detected overall such that the 25 mg

41 .359, P=.023), maximum plasma concentration (Cmax; r2=0.340, P=.028), and plasma HIV RNA decline.

42 D showed a mean maximum serum concentration (Cmax) of 1,209 +/- 430 ng/mL, with a median T1/2 beta fo

43 The median maximum serum concentration (Cmax), area under the curve from 0-8 hours (AUC0-8), tim

44 serum half-life (and maximum concentration [Cmax]) generally increased between the first and fourth

45 apolated to infinity, maximum concentration [Cmax], and time to Cmax) were observed on Day 10 in subj

46 geometric mean maximum plasma concentration [Cmax] and 77% and 82% lower AUC0-t [area under the curve

47 an 176 nM (the maximal plasma concentration [Cmax] with recommended adult dose) in 76% of samples, wh

48 to 72 h, as well as maximal concentrations (Cmax: 2.04 +/- 0.14 compared with 2.73 +/- 0.18 mumol/L)

49 Peak concentrations (Cmax) on day 1 related to mean percentage decrement in n

50 time in which maximum plasma concentrations (Cmax) were achieved averaged 1.22 hours with an average

51 oxicity, maximum radiotracer concentrations (Cmax) in brain and vertebra were low (0.67 and 0.54 m(2)

52 d plasma d6-alpha-tocopherol concentrations (Cmax) and the areas under the curve increased 2- and 3-f

53 AUC for 4-OH-CPA, the finding that 4-OH-CPA Cmax may determine its level of myelotoxicity indicates

54 Furthermore, monitoring 4-OH-CPA Cmax may identify individuals at most risk of CPA side e

55 (0.11-0.37 microM) and at 0.2 mg/kg per day, Cmax was 0.40 and 0.46 microM; area under the concentrat

56 (356+/-63), and 2 hr after the morning dose (Cmax=1567+/-669), decreased from 39+/-16 to 15+/-8 and 3

57 is 24% at a dose of 2 mg/kg with a mean drug Cmax of 145 +/- 46 ng/mL.

58 eneral, maximal levels of DNA scission (i.e. Cmax) varied over a considerably larger range than did t

59 differed by >15% for 17% of pairs; estimated Cmax differed by >15% for 39%.

60 appear more sensitive to the drug exposure (Cmax) where more restrictive labeling occurs.

61 5%) and AUC (27.4%) and, to a lesser extent, Cmax (11%).

62 the 82 patients was 101.1 to 114.5% and for Cmax was 83.0% to 112.7%.

63 Except for Cmax, which was 19.5% higher after IV drug administratio

64 nce limits (lowest and highest CI limits for Cmax, 92.6% and 110.4%; for AUC0-96, 96.9% and 101.9%).

65 lidations as the prediction errors (%PE) for Cmax and AUC were less than 15%.

66 content in the plasma chylomicron fraction (Cmax).

67 Twenty-six percent of patients had Cmax of rifampicin <8 mg/L, pyrazinamide <35 mg/L, and i

68 91.4% and yield of 68.3%, and 4-fold higher Cmax and AUC over the slow-releasing ATRA formulation.

69 imiting neutropenia had significantly higher Cmax values than patients who did not, whereas nonhemato

70 ent of variation [CV], approximately 40%) in Cmax and area under the concentration-time curve from 0

71 AMP resulted in a dose-dependent increase in Cmax and AUC(0-24h) of 2F-ara-A and achieved an AUC(0-24

72 consumption correlated with the increase in Cmax when felodipine was taken with either the 1st or th

73 Intersubject variability in Cmax and AUC(0-t) was small and similar for reference an

74 Interpatient variability in Cmax,ss and AUCtau,ss was estimated to be 65% and 71% re

75 okinetic evaluation in dogs showed increased Cmax (39.18 +/- 7.34 vs 21.68 +/- 6.3 mug.dL-1), higher

76 te prodrugs led to a substantially increased Cmax and prolonged availability of FimH antagonists in u

77 mer conjugate did not produce a high initial Cmax of SN-38.

78 a with no subject x formulation interaction (Cmax, 0.00; AUC0-96, 0.54; and AUC0-infinity, 0.36; P >/

79 fied negative interactions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture co

80 /PD analyses using MARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which ther

81 If isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the ison

82 For patients with isoniazid Cmax >4.6 mg/L, higher isoniazid exposures were associat

83 12.11-15.81) and the concentration maximum (Cmax) (range 17.96-24.72) for all products.

84 time of 48 hours and concentration maximum (Cmax) of 4000- to 15,000-fold higher than their therapeu

85 125 was rapidly absorbed with geometric mean Cmax and AUC0-24 h values of 1417 ng/mL and 16 727 h ng/

86 For the CI regimen at MTD, the mean Cmax was 963 +/- 473 ng/mL, with a median T1/2 beta for

87 C was 285.6 +/- 46.4 microg/mL.min with mean Cmax values of 3.38 +/- 0.43 microg/mL at 75 mg/m2.

88 , maximum concentration (Cmax), AUC0-24/MIC, Cmax/MIC, and percentage of time that concentrations per

89 ng/h per mL), Caverage (8.8 +/- 4.2 ng/mL), Cmax (19.2 +/- 9.7 ng/mL), apparent Half-life (11.7 +/-

90 oncentrations peaked at approximately 50 nM (Cmax) and remained elevated for several hours.

91 A 2- to 4-fold greater dose-normalized Cmax was observed for the dog compared to the other spec

92 Food affected variability of Cmax but not AUC(0-t) .

93 The peak (Cmax) was significantly higher after the morning dose th

94 prednisolone concentration in the perfusate (Cmax) by 3.0 and 2.2 fold, respectively.

95 VOO, FVOO increased IRH (P<0.05) and plasma Cmax of hydroxytyrosol sulphate, a metabolite of OOPC 2h

96 MEC ratio, and peak concentration in plasma [Cmax]:MEC ratio) at clinically achievable exposures.

97 In our Neoral-treated sample population, Cmax was associated with the least variable "cyclosporin

98 curve (AUC), maximum concentration postdose (Cmax), minimum concentration postdose (Cmin), time to ma

99 nt toxicokinetic (TK) model to first predict Cmax for in vivo corroboration using therapeutic scenari

100 lted in an improved pharmacokinetic profile (Cmax = 359 ng.h/mL; AUC0-t = 2436 ng.h/mL) and a desirab

101 evealed that poor systemic exposure in rats (Cmax = 44 ng/mL; AUC0-t = 359 ng . h/mL) at 10 mg/kg was

102 isoniazid Cmax was <4.6 mg/L and rifampicin Cmax/MIC <28, the isoniazid concentration had an antagon

103 ctions between isoniazid Cmax and rifampicin Cmax/MIC ratio on 2-month culture conversion.

104 ARS identified isoniazid Cmax and rifampicin Cmax/MIC thresholds below which there is concentration-d

105 PK for 400 mg (day 7) showed Cmax 3.07 muM, Tmax 3.0 hours, t1/2 (half-life) 6.6 hour

106 mus peak concentration (Cmax), and sirolimus Cmax and area under the concentration-time curve were de

107 No differences in initial slope, Cmax, area under curve (AUC), and T1/2 of BNA were found

108 ated by greater values of the initial slope, Cmax, AUC, and shorter T1/2 than men (all ps<0.04).

109 tions differed by <15% in 99% of BE studies; Cmax differed by <15% in 89% of studies.

110 The Cmax : MEC ratio appears to be the parameter most closel

111 The Cmax and Tmax of ziconotide in CSF following intravenous

112 The Cmax was used as a measure of oral bioavailability to al

113 (90% confidence interval, 1.10-1.23) and the Cmax ratio was 1.49 (90% confidence interval, 1.35-1.65)

114 1/2 for 4-OH-CPA was increased 1.8-fold, the Cmax reduced 1.7-fold, and the AUC remained unchanged.

115 ; the t1/2 +/- SE was 9.1 +/- 1.3 hours, the Cmax was 2,549 +/- 291 ng/mL, the Vd was 3.97 +/- 0.95 L

116 cellized lutein, PLGA-NP lutein improved the Cmax in rat plasma by 15.6-fold and in selected tissues

117 r-individual variability was observed in the Cmax and Tmax of many of these compounds in both plasma

118 At a CPA dose of 100 mg/kg, the Cmax, plasma area under the curve (AUC) and half-life we

119 Pharmacokinetics in mice suggested the Cmax to be 12.0 +/- 2.5 mug/mL and 170 +/- 10 ng/mL in t

120 was found to be closely correlated with the Cmax of 4-OH-CPA (r2= 0.80, P = 0.002).

121 These Cmax values were 4- to 15-fold lower than their cytotoxi

122 The mean time to Cmax (9 +/- 2 h), fractional disappearance rates (0.022

123 av]), peak concentration (Cmax), and time to Cmax (tmax) values were calculated from paired intraveno

124 h low intraindividual variation) and time to Cmax were dose independent.

125 y, maximum concentration [Cmax], and time to Cmax) were observed on Day 10 in subjects receiving tedu

126 of plasma disappearance but similar times to Cmax.

127 he curve from 0-8 hours (AUC0-8), time until Cmax (Tmax), and half-life for moxifloxacin were 3.08 (I

128 in pharmacokinetic parameters estimated were Cmax, Tmax, t1/2, elimination rate constant, AUC0-t and

129 in dogs provided modest bioavailability with Cmax = 0.22 microg/mL.

130 at specific sites correlated inversely with Cmax values, indicating that maximal levels of etoposide

131 files were very similar in both species with Cmax decreasing and Tmax increasing with increasing fatt